A clinical trial assessing PL 8331
Latest Information Update: 03 Jan 2022
At a glance
- Drugs PL 8331 (Primary)
- Indications Choroidal neovascularisation; Diabetic retinopathy; Dry eyes
- Focus Adverse reactions
- Sponsors Palatin Technologies
- 03 Jan 2022 New trial record